skip to content
Randomized Double-Blind Phase III Pivotal Field Trial of the Comparative Immunogenicity Safety and Tolerability of Two Yellow Fever 17D Vaccines (ARILVAX(Trademark) and YF-VAX(Trademark)) in Healthy Infants and Children in Peru Preview this item
ClosePreview this item
Checking...

Randomized Double-Blind Phase III Pivotal Field Trial of the Comparative Immunogenicity Safety and Tolerability of Two Yellow Fever 17D Vaccines (ARILVAX(Trademark) and YF-VAX(Trademark)) in Healthy Infants and Children in Peru

Author: Vivian E Belmusto-WornJoel L SanchezKaren McCarthyRichard NicholsChristian T BaustistaAll authors
Publisher: Ft. Belvoir Defense Technical Information Center 17 AUG 2004.
Edition/Format:   eBook : English
Database:WorldCat
Summary:
We conducted a randomized, double-blind, phase III yellow fever (YF) vaccine trial among 1,107 healthy children in Sullana in northern Peru. The safety and efficacy (by measurement of geometric mean neutralizing antibody titer responses) were determined for two YF vaccines, ARILVAX (exp Trademark)" (n 738) and YF-VAX (n 369). Seroconversion rates were higher (94.9%) in ARILVAX(EXP TRADEMARK)" than in YF-VAX (90.6%)  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

 

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Internet resource
Document Type: Internet Resource
All Authors / Contributors: Vivian E Belmusto-Worn; Joel L Sanchez; Karen McCarthy; Richard Nichols; Christian T Baustista; Alan J Magill; Giovanna Pastor-Cauna; Carlos Echevarria; Victor A Laguna-Torres; Billey K Samame; SUTTER INST FOR MEDICAL RESEARCH SACRAMENTO CA.
OCLC Number: 227937417
Notes: Pub. in American Journal Tropical Medicine Hygiene, v72 n2, p.189-197, 2005.
Description: 10 p.

Abstract:

We conducted a randomized, double-blind, phase III yellow fever (YF) vaccine trial among 1,107 healthy children in Sullana in northern Peru. The safety and efficacy (by measurement of geometric mean neutralizing antibody titer responses) were determined for two YF vaccines, ARILVAX (exp Trademark)" (n 738) and YF-VAX (n 369). Seroconversion rates were higher (94.9%) in ARILVAX(EXP TRADEMARK)" than in YF-VAX (90.6%) recipients. The two-sided 95% confidence interval (YF-VAX ARILVAX(EXP TRADEMARK)") was (12.8% to 2.5%), indicating that the higher seroconversion rate for Arilvax" was significant. Post-vaccination (30-day) mean log10 neutralization indices were found to be similar for both products: 1.32 for ARILVAX(EXP TRADEMARK)" and 1.26 for YF-VAX (P 0.1404, by analysis of variance). A similar number of subjects in each group reported at least one adverse event (AE); 441 (59.8%) for ARILVAX(EXP TRADEMARK)" versus 211 (59.9%) for YF-VAX . Most (591; 96.7%) of these were of a mild nature and resolved without treatment. There were no treatment-related serious AEs. This is the first randomized, double-blind comparison of two YF vaccines in a pediatric population; both vaccines were shown to be highly immunogenic and well-tolerated.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


<http://www.worldcat.org/oclc/227937417>
library:oclcnum"227937417"
library:placeOfPublication
library:placeOfPublication
rdf:typeschema:MediaObject
rdf:typeschema:Book
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:contributor
schema:datePublished"17 AUG 2004"
schema:datePublished"2004"
schema:description"We conducted a randomized, double-blind, phase III yellow fever (YF) vaccine trial among 1,107 healthy children in Sullana in northern Peru. The safety and efficacy (by measurement of geometric mean neutralizing antibody titer responses) were determined for two YF vaccines, ARILVAX (exp Trademark)" (n 738) and YF-VAX (n 369). Seroconversion rates were higher (94.9%) in ARILVAX(EXP TRADEMARK)" than in YF-VAX (90.6%) recipients. The two-sided 95% confidence interval (YF-VAX ARILVAX(EXP TRADEMARK)") was (12.8% to 2.5%), indicating that the higher seroconversion rate for Arilvax" was significant. Post-vaccination (30-day) mean log10 neutralization indices were found to be similar for both products: 1.32 for ARILVAX(EXP TRADEMARK)" and 1.26 for YF-VAX (P 0.1404, by analysis of variance). A similar number of subjects in each group reported at least one adverse event (AE); 441 (59.8%) for ARILVAX(EXP TRADEMARK)" versus 211 (59.9%) for YF-VAX . Most (591; 96.7%) of these were of a mild nature and resolved without treatment. There were no treatment-related serious AEs. This is the first randomized, double-blind comparison of two YF vaccines in a pediatric population; both vaccines were shown to be highly immunogenic and well-tolerated."@en
schema:exampleOfWork<http://worldcat.org/entity/work/id/137575526>
schema:inLanguage"en"
schema:name"Randomized Double-Blind Phase III Pivotal Field Trial of the Comparative Immunogenicity Safety and Tolerability of Two Yellow Fever 17D Vaccines (ARILVAX(Trademark) and YF-VAX(Trademark)) in Healthy Infants and Children in Peru"@en
schema:numberOfPages"10"
schema:publication
schema:publisher
schema:url<http://handle.dtic.mil/100.2/ADA468921>
wdrs:describedby

Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.